Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* GADICKE ANSBERT	2. Issuer Name and Ticker or Trading Symbol iTeos Therapeutics, Inc. [ ITOS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O MPM CAPITAL, 450 KENDALL STREET	3. Date of Earliest Transaction (MM/DD/YYYY) 12/3/2021
(Street) CAMBRIDGE, MA 02142 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/3/2021		S⁽¹⁾		29402 ⁽²⁾⁽³⁾	D	$34.68 ⁽⁴⁾	4784185	I	See Footnote ⁽⁵⁾
Common Stock	12/3/2021		S⁽¹⁾		4047 ⁽⁶⁾	D	$35.44 ⁽⁷⁾	4780138	I	See Footnote ⁽⁸⁾
Common Stock	12/3/2021		S⁽¹⁾		300 ⁽⁹⁾	D	$36.26	4779838	I	See Footnote ⁽¹⁰⁾
Common Stock	12/6/2021		S⁽¹⁾		14173 ⁽¹¹⁾	D	$32.35 ⁽¹²⁾	4765665	I	See Footnote ⁽¹³⁾
Common Stock	12/6/2021		S⁽¹⁾		1960 ⁽¹⁴⁾	D	$33.57 ⁽¹⁵⁾	4763705	I	See Footnote ⁽¹⁶⁾
Common Stock	12/6/2021		S⁽¹⁾		850 ⁽¹⁷⁾	D	$34.08 ⁽¹⁸⁾	4762855	I	See Footnote ⁽¹⁹⁾
Common Stock	12/6/2021		S⁽¹⁾		100 ⁽²⁰⁾	D	$35.04	4762755	I	See Footnote ⁽²¹⁾
Common Stock	12/7/2021		S⁽¹⁾		30059 ⁽²²⁾	D	$33.15 ⁽²³⁾	4732696	I	See Footnote ⁽²⁴⁾
Common Stock	12/7/2021		S⁽¹⁾		2499 ⁽²⁵⁾	D	$34.11 ⁽²⁶⁾	4730197	I	See Footnote ⁽²⁷⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:
(1)	Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
(2)	BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(3)	The shares were sold as follows: 10,467 by MPM BioVentures 2014, L.P. ("BV 2014"), 359 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,612 by MPM BioVentures 2018, L.P. ("BV 2018"), 131 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 11,833 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.
(4)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.15 to $35.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(5)	The shares are held as follows: 1,651,193 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 56,834 by AM BV2014, 1,042,857 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 20,593 by AM BV2018 and 1,866,453 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(6)	The shares were sold as follows: 1,441 by BV 2014, 50 by AM BV2014, 910 by BV 2018, 18 by AM BV2018 and 1,628 by UBS Oncology.
(7)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.15 to $36.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(8)	The shares are held as follows: 1,649,752 by BV 2014, 97,289 by BV 2014(B), 56,784 by AM BV2014, 1,041,947 by BV 2018, 48,966 by BV 2018(B), 20,575 by AM BV2018 and 1,864,825 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(9)	The shares were sold as follows: 107 by BV 2014, 4 by AM BV2014, 67 by BV 2018, 1 by AM BV2018 and 121 by UBS Oncology.
(10)	The shares are held as follows: 1,649,645 by BV 2014, 97,289 by BV 2014(B), 56,780 by AM BV2014, 1,041,880 by BV 2018, 48,966 by BV 2018(B), 20,574 by AM BV2018 and 1,864,704 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(11)	The shares were sold as follows: 5,046 by BV 2014, 173 by AM BV2014, 3,187 by BV 2018, 63 by AM BV2018 and 5,704 by UBS Oncology.
(12)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.98 to $32.975 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(13)	The shares are held as follows: 1,644,599 by BV 2014, 97,289 by BV 2014(B), 56,607 by AM BV2014, 1,038,693 by BV 2018, 48,966 by BV 2018(B), 20,511 by AM BV2018 and 1,859,000 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(14)	The shares were sold as follows: 698 by BV 2014, 24 by AM BV2014, 441 by BV 2018, 8 by AM BV2018 and 789 by UBS Oncology.
(15)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.99 to $33.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(16)	The shares are held as follows: 1,643,901 by BV 2014, 97,289 by, 56,583 by AM BV2014, 1,038,252 by BV 2018, 48,966 by BV 2018(B), 20,503 by AM BV2018 and 1,858,211 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(17)	The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014, 191 by BV 2018, 4 by AM BV2018 and 342 by UBS Oncology.
(18)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.125 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(19)	The shares are held as follows: 1,643,598 by BV 2014, 97,289 by BV 2014(B), 56,573 by AM BV2014, 1,038,061 by BV 2018, 48,966 by BV 2018(B), 20,499 by AM BV2018 and 1,857,869 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(20)	The shares were sold as follows: 35 by BV 2014, 2 by AM BV2014, 22 by BV 2018, 1 by AM BV2018 and 40 by UBS Oncology.
(21)	The shares are held as follows: 1,643,563 by BV 2014, 97,289 by BV 2014(B), 56,571 by AM BV2014, 1,038,039 by BV 2018, 48,966 by BV 2018(B), 20,498 by AM BV2018 and 1,857,829 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(22)	The shares were sold as follows: 10,701 by BV 2014, 368 by AM BV2014, 6,759 by BV 2018, 134 by AM BV2018 and 12,097 by UBS Oncology.
(23)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(24)	The shares are held as follows: 1,632,862 by BV 2014, 97,289 by BV 2014(B), 56,203 by AM BV2014, 1,031,280 by BV 2018, 48,966 by BV 2018(B), 20,364 by AM BV2018 and 1,845,732 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(25)	The shares were sold as follows: 890 by BV 2014, 31 by AM BV2014, 562 by BV 2018, 11 by AM BV2018 and 1,005 by UBS Oncology.
(26)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.875 to $34.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(27)	The shares are held as follows: 1,631,972 by BV 2014, 97,289 by BV 2014(B), 56,172 by AM BV2014, 1,030,718 by BV 2018, 48,966 by BV 2018(B), 20,353 by AM BV2018 and 1,844,727 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
GADICKE ANSBERT C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
UBS Oncology Impact Fund L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
BioImpact Capital LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
Oncology Impact Fund (Cayman) Management L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X

Signatures
/s/ Ansbert Gadicke		12/7/2021
^**Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P., the general partner of UBS Oncology Impact Fund L.P		12/7/2021
^**Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC		12/7/2021
^**Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P.		12/7/2021
^**Signature of Reporting Person		Date